杜普伊特伦挛缩症市场 - 全球产业规模、份额、趋势、机会及预测（按类型、疾病类型、最终用途、地区和竞争格局划分，2021-2031年）

全球杜普伊特伦氏挛缩症市场预计将从 2025 年的 46.8 亿美元成长到 2031 年的 61.5 亿美元，复合年增长率为 4.66%。

杜普伊特伦挛缩症是一种进行性结缔组织疾病，其特征是掌筋膜增厚，导致胶原蛋白结节和索状物的形成，最终造成手指永久性挛缩。市场成长的主要驱动因素是全球人口老化和糖尿病等风险因素的增加，这些因素导致患者群体不断扩大。此外，患者对微创治疗的偏好日益增长，以及治疗方法的日益普及，也扩大了可治疗的病例范围。根据美国整形外科医师协会的数据，预计到2024年，其会员外科医师将进行208,480例手部重组手术，显示包括Dupuytren氏挛缩在内的功能性手术需求持续且显着。

阻碍市场扩张的主要障碍之一是现有治疗方案的高疾病復发率。无论患者选择手术切除术或微创酶注射，由于缺乏永久治疗方法，往往需要反覆干预，从而加重患者和支付方的经济负担。长期疗效问题，加上通常适用于高成本生物疗法的严格报销政策，可能会限制在註重成本的医疗保健市场中采用高端治疗方案。

市场驱动因素

全球杜普伊特伦挛缩症市场的主要成长动力是研发投入的激增，这些投入主要集中在新型治疗方法上，而这又源于对安全性更高的非手术治疗方法的迫切需求。生技公司正积极推进其临床研发管线，以期推出现有胶原蛋白酶疗法的重组替代方案，从而减少对侵入性手术的依赖。例如，Connext公司于2024年7月宣布，其在澳洲进行的I/II期临床试验中已完成CNT201的首剂生物製药，这标誌着检验新型重组胶原蛋白酶治疗方法疗效的重要一步。预计这种研发活动的活性化将催生出疗效更佳、成本更低的治疗方法，从而丰富市场竞争格局并扩大市场进入。

同时，全球发病率的上升，尤其是在老年人族群中，导致需要长期医疗管理的患者数量不断增加。随着预期寿命的延长，遗传易感性和生活方式相关风​​险的累积，使得基层医疗机构的诊断病例显着增加，直接扩大了目标患者群体。 2024年7月发表在medRxiv上的一项研究分析了全科诊所的註册数据，发现研究人群中杜普伊特伦挛缩症的总体患病率为1.99%，其中老年人群的患病率显着高于其他人群。患者数量的增加导致对现有药物治疗的巨大商业性需求。例如，Endo公司在2024年11月公布的第三季XIAFLEX系列产品总营收为1.28亿美元，证实了这项临床需求所蕴含的显着规模经济效益。

市场挑战

高復发率仍是全球杜普伊特伦挛缩症市场持续成长的一大障碍。这种临床现实导致患者需要反覆治疗，使人们对昂贵治疗方案的长期经济价值产生质疑。在症状频繁復发、导致医疗成本增加的情况下，保险公司和支付方越来越不愿意核准高成本的生物製药疗法和微创手术。因此，这种质疑导致了严格的报销标准，优先考虑传统的、成本较低的手术方法，而非创新但更昂贵的药物治疗方案，从而限制了新型治疗药物生产商的收入潜力。

2024年，英国手外科协会透过对比临床数据强调了这个问题：接受微创胶原蛋白酶注射治疗的患者一年内再次手术率为14.6%，而接受外科切除术的患者再次手术率则显着降低至3.4%。这种初始疗效的差异加剧了注重成本的医疗系统不愿广泛资助先进的非手术治疗，直接阻碍了高端生物製药市场份额的成长。

市场趋势

经皮筋膜切开术 (PNA) 的日益普及标誌着治疗理念正发生重大转变，即从激进的手术切除转向微创、经济高效的治疗方法，优先考虑快速恢復功能。随着越来越多的临床医生寻求可高度重复的门诊手术，以最大限度地减少患者的恢復时间和医疗成本，尤其是在传统手术风险过高的情况下，这一趋势正在加速发展。近期临床数据支持了先进的针刺技术在恢復手指功能方面的有效性，且无需切除术相关的大规模復健过程。根据 2025 年 1 月《肌肉骨骼外科》杂誌的一项研究，一项评估改良 PNA 技术的研究报告显示，受累手指的挛缩平均改善率达 83%，短期復发率显着降低至 14.2%。这使得该手术成为保留手指功能的有效一线治疗方案。

同时，市场正着力将辅助放射线治疗作为一种策略性治疗手段，以延缓疾病进展并解决原发治疗后高復发率的问题。这种方法代表着治疗模式向混合治疗方法模式的转变，即在淋巴结清扫或有限释放后立即进行放射线治疗，惰性纤维母细胞并阻止胶原蛋白索的再形成。目前，重点在于确定这种联合治疗的安全性、扩大保险覆盖范围并提高临床接受度。正如2025年2月《手外科杂誌》（欧洲版）报道，一项评估辅助放射线治疗安全性的随机对照试验证实了其良好的耐受性。记录的不利事件中有89%为轻度且可自愈，这支持了其作为一种低风险辅助性治疗在长期疾病控制中的作用。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球杜普伊特伦挛缩症市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 类型（诊断（身体检查、X光检查）、治疗（手术、放射线治疗、针刺筋膜切开术、类固醇注射、酵素注射、职能治疗、其他））
  • 依疾病类型（I型、II型、III型）
  • 依最终使用者（医院、诊所、学术/研究机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美杜普伊特伦挛缩症市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲杜普伊特伦挛缩症市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区杜普伊特伦挛缩症市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲杜普伊特伦挛缩症市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲杜普伊特伦挛缩症市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球杜普伊特伦挛缩症市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Nantong Jinghua Pharmaceutical Co., Ltd
• Actiza Pharmaceutical Private Limited
• Endo International plc
• Spear Pharmaceuticals
• Hikma Pharmaceuticals PLC
• Bristol-Myers Squibb
• Glaxosmithkline PLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Dupuytren's Disease Market is projected to expand from a valuation of USD 4.68 Billion in 2025 to USD 6.15 Billion by 2031, registering a Compound Annual Growth Rate (CAGR) of 4.66%. Dupuytren's disease is defined as a progressive connective tissue disorder involving the thickening of the palmar fascia, which results in the development of collagen nodules and cords that force fingers into permanent contracture. Market growth is primarily supported by an aging global population and the increasing prevalence of risk factors such as diabetes, both of which widen the target patient demographic. Additionally, a growing patient preference and availability of minimally invasive treatments have expanded the range of manageable cases. Data from the American Society of Plastic Surgeons indicates that 208,480 reconstructive hand surgeries were performed by member surgeons in 2024, highlighting the consistent and substantial demand for functional interventions, including those required for Dupuytren's contracture.

One significant obstacle potentially hindering market expansion is the high rate of disease recurrence linked to current treatment options. Whether patients choose surgical fasciectomy or minimally invasive enzymatic injections, the absence of a permanent cure frequently leads to the need for repeat interventions, compounding the economic burden on both patients and payers. This issue regarding long-term efficacy, coupled with strict reimbursement policies often applied to high-cost biologic therapies, threatens to restrict the adoption of premium treatment solutions in cost-conscious healthcare markets.

Market Driver

A primary engine for growth in the Global Dupuytren's Disease Market is the surge in research and development dedicated to novel therapeutics, driven by an urgent demand for non-surgical interventions with enhanced safety profiles. Biotechnology companies are actively progressing their clinical pipelines to introduce recombinant alternatives to existing collagenase therapies, with the goal of reducing reliance on invasive surgical procedures. For example, Connext announced in July 2024 that it had administered the first dose of CNT201 to patients in a Phase 1/2 clinical trial in Australia, representing a pivotal step toward validating a new genetically recombinant collagenase treatment. This intensification of R&D activity is expected to diversify the competitive landscape and broaden market access by developing treatments that offer superior efficacy or cost benefits compared to current biologics.

Simultaneously, the increasing global prevalence of the condition, particularly within aging demographics, is expanding the volume of patients necessitating long-term medical management. As life expectancy increases, the accumulation of genetic predispositions and lifestyle-related risks has led to a measurable rise in diagnosed cases in primary care settings, directly enlarging the addressable patient pool. A study published via medRxiv in July 2024 analyzed general practice registration data and identified an overall Dupuytren's disease prevalence of 1.99% in the population studied, with rates peaking significantly in older age groups. This growing patient base translates into substantial commercial demand for established pharmaceutical interventions, as evidenced by Endo, Inc., which reported total third-quarter revenues of $128 million for its XIAFLEX franchise in November 2024, underscoring the significant economic scale fueled by this clinical need.

Market Challenge

The high rate of disease recurrence remains a critical barrier impeding the sustainable growth of the Global Dupuytren's Disease Market. This clinical reality generates a cycle of repeat interventions that calls into question the long-term economic value of premium treatment options. Insurance providers and payers are increasingly reluctant to authorize high-cost biologic therapies or minimally invasive procedures when the condition frequently returns, necessitating additional medical expenditures. Consequently, this skepticism results in stringent reimbursement criteria that favor traditional, lower-cost surgical methods over innovative but expensive pharmaceutical solutions, thereby limiting the revenue potential for manufacturers of novel therapeutics.

In 2024, the British Society for Surgery of the Hand highlighted this issue with comparative clinical data showing that patients treated with minimally invasive collagenase injections experienced a re-intervention rate of 14.6 percent within one year, whereas those undergoing surgical fasciectomy saw a significantly lower rate of 3.4 percent. This disparity in early efficacy reinforces the hesitation of cost-sensitive healthcare systems to broadly fund advanced non-surgical treatments, directly hampering the market share expansion of premium biological products.

Market Trends

The increasing adoption of Percutaneous Needle Aponeurotomy (PNA) signifies a major shift toward minimally invasive, cost-effective interventions that prioritize rapid functional recovery over aggressive surgical excision. This trend is accelerating as clinicians seek repeatable outpatient procedures that minimize patient downtime and healthcare costs, especially for cases where traditional open surgery presents disproportionate risks. Recent clinical data supports the efficacy of refined needle techniques in restoring hand function without the extensive rehabilitation associated with fasciectomy. According to Musculoskeletal Surgery in January 2025, a study evaluating a modified PNA technique reported a mean contracture correction of 83 percent across affected digits, with a notably low short-term recurrence rate of 14.2 percent, positioning the procedure as a viable first-line treatment for preserving hand mechanics.

Concurrently, the market is observing the integration of adjuvant radiotherapy as a strategic modality to inhibit disease progression and address the challenge of high recurrence rates following primary interventions. This approach represents a move toward hybrid treatment models where radiotherapy is applied immediately after nodule disruption or limited release to deactivate fibroblasts and prevent the reforming of collagen cords. The focus is currently on establishing the safety profile of this combination to encourage broader payer coverage and clinical acceptance. As reported in the Journal of Hand Surgery (European Volume) in February 2025, a randomized controlled trial assessing the safety of adjuvant radiotherapy confirmed its tolerability, revealing that 89 percent of recorded adverse events were mild and self-limiting, thereby supporting its role as a low-risk adjunct for long-term disease control.

Key Market Players

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Nantong Jinghua Pharmaceutical Co., Ltd
• Actiza Pharmaceutical Private Limited
• Endo International plc
• Spear Pharmaceuticals
• Hikma Pharmaceuticals PLC
• Bristol-Myers Squibb
• Glaxosmithkline PLC

Report Scope

In this report, the Global Dupuytren's Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dupuytren's Disease Market, By Type

• Diagnosis (Physical Examination, X-ray)
• Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others)

Dupuytren's Disease Market, By Disease Type

• Type I
• Type II
• Type III

Dupuytren's Disease Market, By End-use

• Hospitals
• Clinics
• Academic & Research Institute
• Others

Dupuytren's Disease Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dupuytren's Disease Market.

Available Customizations:

Global Dupuytren's Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dupuytren's Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Diagnosis (Physical Examination, X-ray), Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, Others))
  • 5.2.2. By Disease Type (Type I, Type II, Type III)
  • 5.2.3. By End-use (Hospitals, Clinics, Academic & Research Institute, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Dupuytren's Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Disease Type
  • 6.2.3. By End-use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dupuytren's Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By End-use
  • 6.3.2. Canada Dupuytren's Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By End-use
  • 6.3.3. Mexico Dupuytren's Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By End-use

7. Europe Dupuytren's Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Disease Type
  • 7.2.3. By End-use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Dupuytren's Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By End-use
  • 7.3.2. France Dupuytren's Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By End-use
  • 7.3.3. United Kingdom Dupuytren's Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By End-use
  • 7.3.4. Italy Dupuytren's Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By End-use
  • 7.3.5. Spain Dupuytren's Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By End-use

8. Asia Pacific Dupuytren's Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Disease Type
  • 8.2.3. By End-use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Dupuytren's Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By End-use
  • 8.3.2. India Dupuytren's Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By End-use
  • 8.3.3. Japan Dupuytren's Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By End-use
  • 8.3.4. South Korea Dupuytren's Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By End-use
  • 8.3.5. Australia Dupuytren's Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By End-use

9. Middle East & Africa Dupuytren's Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Disease Type
  • 9.2.3. By End-use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Dupuytren's Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By End-use
  • 9.3.2. UAE Dupuytren's Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By End-use
  • 9.3.3. South Africa Dupuytren's Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By End-use

10. South America Dupuytren's Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Disease Type
  • 10.2.3. By End-use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Dupuytren's Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By End-use
  • 10.3.2. Colombia Dupuytren's Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By End-use
  • 10.3.3. Argentina Dupuytren's Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Dupuytren's Disease Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Bayer AG
• 15.4. Nantong Jinghua Pharmaceutical Co., Ltd
• 15.5. Actiza Pharmaceutical Private Limited
• 15.6. Endo International plc
• 15.7. Spear Pharmaceuticals
• 15.8. Hikma Pharmaceuticals PLC
• 15.9. Bristol-Myers Squibb
• 15.10. Glaxosmithkline PLC

16. Strategic Recommendations

17. About Us & Disclaimer